Developing immunotherapy as legitimate therapy for patients with prostate cancer
- PMID: 20100956
- DOI: 10.1200/JCO.2009.26.3483
Developing immunotherapy as legitimate therapy for patients with prostate cancer
Comment on
-
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100959 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical